MarketCapExport financials
Chinook Therapeutics (KDNY)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Chinook Therapeutics Balance Sheet 2022-2011 | KDNY
Brief overview of Chinook Therapeutics's balance sheet structure
The review uses the five latest available annual reports between 2018 and 2022.
Total assets increased by +60.6%, from $357.5 million to $574.1 million. A CAGR near 12.6% points to substantial expansion.
Liabilities grew more slowly than assets: -40.5% versus +60.6%. Expansion relied more on equity, improving funding quality.
The equity-to-assets ratio is 77%, compared with -0.2% five periods ago. The balance sheet has a substantial internal cushion.
Net debt moved below zero to -$76 million, reflecting surplus cash over debt.
Cash represents 20.1% of assets versus 35.3% initially, showing how the immediate liquidity reserve changed.
The balance sheet carries negative retained earnings of -$419.6 million. The figure may result from accumulated losses or an active capital return policy.
Overall assessment
Chinook Therapeutics has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet Chinook Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-76 M | -138 M | -146 M | -10.9 M | - | - | - | - | - | - | - | - |
Long Term Debt |
34.5 M | 39.6 M | 38.7 M | 114 K | - | - | - | - | - | - | - | - |
Long Term Debt Current |
4.95 M | 4.4 M | 3.04 M | 163 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 940 K | - | - | - | - | - | - | - | - |
Total Current Liabilities |
50.8 M | 40.1 M | 22.8 M | 2.43 M | 30.5 M | 41.4 M | 30.6 M | 31.1 M | 44.2 M | - | - | - |
Total Liabilities |
132 M | 110 M | 94.4 M | 37 M | 222 M | 208 M | 211 M | 220 M | 47.8 M | - | - | - |
Deferred Revenue |
- | - | 95 K | 6.95 M | 16 M | 14.9 M | 15.1 M | 15 M | 33.4 M | - | - | - |
Retained Earnings |
-420 M | -232 M | -129 M | -47.2 M | -405 M | -284 M | -192 M | -101 M | -61.6 M | - | - | - |
Total Assets |
574 M | 564 M | 429 M | 15.7 M | 358 M | 445 M | 439 M | 482 M | 126 M | - | - | - |
Cash and Cash Equivalents |
115 M | 182 M | 188 M | 11.2 M | 126 M | 158 M | 74.9 M | 150 M | 119 M | 8.53 M | - | - |
Book Value |
442 M | 454 M | 335 M | -21.3 M | 135 M | 237 M | 227 M | 262 M | 78.7 M | - | - | - |
Total Shareholders Equity |
442 M | 454 M | 335 M | -41.1 M | -681 K | 237 M | 227 M | 262 M | -61.3 M | -38.8 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Chinook Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
29.7 M | 33.2 M | 34.5 M | 35.8 M | 37.2 M | 38.5 M | 39.6 M | 40.8 M | 37.1 M | 38 M | 38.7 M | 30.4 M | 30.9 M | 31.3 M | 114 K | 32.1 M | 32.6 M | 33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
132 M | 131 M | 132 M | 116 M | 94.1 M | 104 M | 110 M | 114 M | 111 M | 98.3 M | 94.4 M | 212 M | 219 M | 226 M | 37 M | 231 M | 237 M | 240 M | 222 M | 211 M | 222 M | 226 M | 208 M | 209 M | 206 M | 206 M | 211 M | 217 M | 224 M | 228 M | 220 M | 215 M | 232 M | 51.1 M | 47.8 M | 47.8 M | 47.8 M | 47.8 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | 95 K | 95 K | 95 K | 95 K | 3.79 M | 4.94 M | 5.81 M | 6.95 M | 16 M | 16 M | 16 M | 16 M | 17.7 M | 17.6 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 15 M | 15.1 M | 15.2 M | 15.2 M | 15 M | 15 M | 19.7 M | 17.8 M | 26.9 M | 33.4 M | 33.4 M | 33.4 M | 33.4 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-547 M | -480 M | -420 M | -357 M | -301 M | -263 M | -232 M | -239 M | -209 M | -166 M | -129 M | -526 M | -511 M | -494 M | -47.2 M | -467 M | -447 M | -428 M | -405 M | -378 M | -355 M | -331 M | -284 M | -258 M | -233 M | -214 M | -192 M | -162 M | -127 M | -130 M | -101 M | -104 M | -105 M | -78.3 M | -61.6 M | -61.6 M | -61.6 M | -61.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
489 M | 544 M | 574 M | 590 M | 601 M | 531 M | 564 M | 383 M | 408 M | 399 M | 429 M | 247 M | 265 M | 285 M | 15.7 M | 313 M | 338 M | 356 M | 358 M | 369 M | 398 M | 423 M | 445 M | 465 M | 464 M | 435 M | 439 M | 467 M | 470 M | 468 M | 482 M | 458 M | 473 M | 139 M | 126 M | 126 M | 126 M | 126 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
127 M | 118 M | 115 M | 126 M | 146 M | 104 M | 182 M | 109 M | 135 M | 168 M | 190 M | 72.6 M | 71.1 M | 94.4 M | 11.2 M | 53.6 M | 79.6 M | 113 M | 126 M | 121 M | 114 M | 100 M | 158 M | 159 M | 184 M | 107 M | 74.9 M | 98 M | 106 M | 120 M | 150 M | 181 M | 466 M | 133 M | 119 M | 119 M | 119 M | 119 M | 8.53 M | - | - | - | 3.7 M | - | - | - | - | - | - | - |
Book Value |
357 M | 412 M | 442 M | 475 M | 507 M | 427 M | 454 M | 270 M | 297 M | 301 M | 335 M | 34.5 M | 46.6 M | 59.6 M | -21.3 M | 82 M | 101 M | 115 M | 135 M | 158 M | 176 M | 197 M | 237 M | 256 M | 258 M | 229 M | 227 M | 250 M | 246 M | 240 M | 262 M | 243 M | 241 M | 87.7 M | 78.7 M | 78.7 M | 78.7 M | 78.7 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
357 M | 412 M | 442 M | 475 M | 507 M | 427 M | 454 M | 270 M | 297 M | 301 M | 335 M | 34.5 M | 46.6 M | 59.6 M | -41.1 M | 82 M | 101 M | 115 M | -681 K | 158 M | 176 M | 197 M | 237 M | 256 M | 258 M | 229 M | 227 M | 250 M | 246 M | 240 M | 262 M | 243 M | 241 M | -77.3 M | -61.3 M | -61.3 M | -61.3 M | -61.3 M | -38.8 M | - | - | - | -27.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Chinook Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Russia
Canada
Israel
Britain
Singapore
China
Schweiz
